Scientist, Cancer Biology
Merrimack Pharmaceuticals is a biopharmaceutical company discovering, developing and preparing to commercialize innovative medicines paired with companion diagnostics for the treatment of serious diseases, with an initial focus on cancer. Merrimack applies Network Biology, its proprietary systems biology-based approach to biomedical research, throughout the research and development process. Merrimack currently has six targeted therapeutic oncology candidates in clinical development.
One of our product candidates, MM-111, is a bispecific antibody targeting ErbB2 and inhibiting ErbB3. MM-111 is currently in Phase I and Phase II trials in a variety of cancer indications and is being developed concurrently with a multiplexed diagnostic assay designed to identify patients that are predicted to respond to MM-111.
We are looking for an innovative scientist to investigate the molecular mechanisms by which MM-111 combines with standard-of-care therapies for our indications of interest and to help define the patient populations most likely to benefit from these combinations. This will have a direct impact on rationally designing the best treatment regimens in the clinic, along with the most predictive companion diagnostic. Responsibilities will include:
- Designing and executing experiments aimed at identifying the pathways responsible for the observed synergy between MM-111 and standard-of-care drugs and the ability of MM-111 to overcome resistance to these drugs both in vitro and in vivo.
- Identifying positive and/or negative biomarkers for these combination treatments.
- Staying current with relevant literature and technological developments in the field.
- Presenting research findings internally, as well as at relevant scientific meetings.
As part of a multidisciplinary team, this person will closely interact with computational modelers and clinicians.
- A recent Ph.D. graduate in a biological, biochemical, bioengineering, or biophysics discipline with no more than one year of postdoctoral experience. Alternatively, a MSc. graduate in a biological, biochemical, bioengineering, or biophysics discipline with at least 3 years of biotechnology/pharmaceutical industry experience will also be considered.
- Experience in dissecting signaling pathways in vitro by chemical or biological means. Experience with small animal models and automation is highly desirable. Proficiency with tissue culture is required.
- Ability to analyze large datasets (by Excel/Prism/MatLab) is required.
We are seeking a highly motivated individual who thrives in multidisciplinary teams and is passionate about changing the paradigm of drug discovery and development.
If you are interested in a great opportunity with a fantastic company, please click the link below to apply!
MassBio is a not-for-profit organization committed to advancing the development of critical new science, technology and medicines that benefit people worldwide.
Founded in 1985, MassBio represents over 600 biotechnology companies, academic institutions, research hospitals, and service organizations involved in life sciences and health care, and works to advance policy and promote education, while providing member programs and events, industry information, and services.
- May 22, 2013 Drug Repurposing and Reformulation: At the Crossroads of IP, Clinical and Business Strategies
- May 8, 2013 MassBio Recognizes Marlborough as a Major Massachusetts Life Sciences Hub: City Biz List - 5/6/2013
- May 8, 2013 Marlborough commended as tech hub: MetroWest Daily News - 5/7/2013
- May 6, 2013 MassBio Recognizes Marlborough as a Major Life Sciences Hub in Massachusetts: PR.com - 5/5/2013
- May 6, 2013 Elections may have big impact on tech, biotech: Boston Globe - 5/5/2013